Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced ...

Myriad Genetics (MYGN) stock is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue ...

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.

Myriad Genetics (MYGN) announced MyRisk Hereditary Cancer Test-the gold standard in germline testing-has been expanded to include genes referenced ...

Myriad Genetics has broadened the scope of its MyRisk Hereditary Cancer Test for germline testing, adding genes.

Genetic testing has had a shift in the past ten years, as it has left medical laboratories and entered living rooms.

Myriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted ...

Myriad Genetics has seen a subtle but notable uptick in its fair value estimate, with analysts revising the figure from $7.95 to $8.29. This slight increase comes as experts reassess the company's ...

SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk®Hereditary Cancer Test —the gold ...

Earlier this year, researchers at Children's Hospital of Philadelphia and Penn created a first-of-its-kind drug customized to ...

Radboudumc and Maastricht UMC+ are the first hospitals in the world to use a new genetic test to diagnose rare diseases on a ...

Get key insights from Myriad Genetics’ Q3 2025 earnings call, growth strategies, financial outlook, and new product launches.